大分割区域淋巴结照射在乳腺癌患者中的疗效与毒性
该回顾性分析纳入154例接受大分割区域淋巴结照射(HF-RNI)的淋巴结阳性或高危淋巴结阴性乳腺癌患者,中位剂量40 Gy/16次,中位随访65.4个月。结果显示慢性臂丛神经病发生率2.0%、上肢淋巴水肿10.5%,晚期心脏和肺毒性率分别为0.7%和3.3%,5年无局部复发生存率98.0%、无区域复发生存率99.3%、无病生存率90.1%、总生存率88.1%。结论认为HF-RNI慢性毒性低且疾病控制优异,支持更广泛临床应用,但需随机试验长期结果确认。
要点
- HF-RNI后慢性臂丛神经病2.0%、上肢淋巴水肿10.5%,晚期心脏毒性0.7%、肺毒性3.3%。
- 5年LRFS 98.0%、RRFS 99.3%、DFS 90.1%、OS 88.1%,疾病控制优异。
- 中位剂量40 Gy/16次,支持HF-RNI临床推广,但需随机试验长期证据。
核心结论
- HF-RNI表现出低慢性毒性率和优异疾病控制,支持更广泛临床应用,但需随机试验长期结果确认。
研究设计与样本
- 回顾性分析纳入154例淋巴结阳性或高危淋巴结阴性乳腺癌患者,2008至2020年接受HF-RNI(>2 Gy/次)。
- 中位剂量40 Gy/16次,照射乳腺/胸壁/重建乳腺及区域淋巴结;主要终点为慢性毒性发生率。
主要发现
- 中位随访65.4个月(范围4-170个月),中位年龄58岁(IQR 48.3-71.0)。
- 慢性臂丛神经病2.0%、活动范围受限1.3%、上肢淋巴水肿10.5%;晚期心脏毒性0.7%、肺毒性3.3%。
- 5年LRFS 98.0%、RRFS 99.3%、DFS 90.1%、OS 88.1%。
关键数值与推荐
- HF-RNI定义为>2 Gy/次;中位剂量40 Gy/16次。
- 前哨淋巴结活检49.4%、腋窝淋巴结清扫47.4%、未行腋窝手术3.2%。
- RNI靶区包括锁骨上及腋窝1-3级淋巴结者65.6%,仅锁骨上及3级者34.4%,内乳淋巴结照射7例(4.7%)。
临床怎么用
- 对淋巴结阳性或高危淋巴结阴性乳腺癌患者,HF-RNI可作为区域淋巴结照射方案,慢性毒性低且疾病控制良好。
局限性
- 回顾性 design,样本量154例,需随机试验长期结果提供确定性证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Regional nodal irradiation (RNI) is increasingly used in place of axillary lymph node dissection (ALND) in carefully selected breast cancer patients. Although hypofractioned whole breast irradiation is standard for node-negative disease, long-term data on hypofractionated RNI (HF-RNI) are limited. This study aims to assess the long-term safety and effectiveness of HF-RNI for breast cancer patients. METHODS AND MATERIALS: This retrospective analysis included 154 patients with node-positive or high-risk node-negative breast cancer treated with HF-RNI (>2 Gy/fraction) between 2008 and 2020. Median dose was 40 Gy/16 fractions to the breast, chest wall, or reconstructed breast as well as regional nodes. The primary endpoint was the incidence of chronic toxicity. Secondary endpoints were acute toxicity, local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), disease-free survival (DFS), and overall survival (OS). Acute toxicities were defined as those occurring during radiation therapy or within 90 days post-treatment; chronic toxicities were defined as those persisting or arising at least 180 days after radiation completion. RESULTS: Median follow-up was 65.4 months (range, 4-170 months). Median age was 58 years (interquartile range, 48.3-71.0). Sentinel lymph node biopsy was performed in 49.4% of patients, 47.4% underwent ALND, and 3.2% had no axillary surgery. RNI targets included supraclavicular and axillary level 1 to 3 nodes in 65.6% of patients, whereas 34.4% were treated only to the supraclavicular and level 3 nodes. There were 7 (4.7%) patients that had internal mammary nodes treated. Chronic brachial plexopathy occurred in 2.0% of patients, limited range of motion in 1.3%, and upper extremity lymphedema in 10.5%. Late cardiac and lung toxicity rates were low at 0.7% and 3.3%, respectively. Five-year actuarial rates of LRFS, RRFS, DFS, and OS were 98.0%, 99.3%, 90.1%, and 88.1%, respectively. CONCLUSIONS: HF-RNI demonstrates low rates of chronic toxicity and excellent disease control, supporting wider adoption in clinical practice. Long-term results of randomized trials of HF-RNI are needed for definitive evidence.
引用
- Spiegel DY, Willcox J, Levey J, et al. The Efficacy and Toxicity of Hypofractionated Regional Nodal Irradiation in Breast Cancer Patients. Pract Radiat Oncol. 2025. PMID: 40311918. doi:10.1016/j.prro.2025.03.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。